Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive ...

Posted 2024-11-08, Longview News-Journal

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 8, 2024 /PRNewswire/ -- Harbour BioMed (the... read full story

Ask about this article

Answer for your question of the article will be displayed here ...

Related News

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

PR Newswire 2024-11-08, 09:50

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

PR Newswire 2024-11-15, 02:00

RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China

PR Newswire 2024-10-29, 04:09

Related News

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

PR Newswire
2024-10-31, 00:15

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC ...

Business Wire
2024-11-11, 14:10

Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology

PR Newswire
2024-11-12, 12:06

argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China Form 6 K (arGEN-X SE)

Public Technologies
2024-11-12, 15:50

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab

PR Newswire
2024-11-01, 02:39

Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson's Disease

PR Newswire
2024-11-12, 11:34

Kling Biotherapeutics to Present Key Applications for its Primary B-Cell Immortalization, Screening and Antibody Optimization Platform Technologies at PEGS Europe

PR Newswire
2024-10-31, 08:41

CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

PR Newswire
2024-10-31, 07:10